Febrile neutropenia (FN) remains one of the most commonly encountered oncologic emergencies in patients (pts) with hematological malignancies. Development of a prognostic system will help to improve the outcome in those pts.
This is a prospective observational study including 142 pts with haematological malignancies who presented to Kasr Al Ainy Center of Clinical Oncology during the period 1st of June 2014 to October 2015. This group of pts suffered from 270 episodes. According to the MASCC score, high risk pts were treated inpatients. All admitted pts were subjected to blood, sputum, stool and urine cultures withdrawal and Galactomann test. PCR (polymerase chain reaction) of sepsis and BAL (broncho-alveloar lavage ) were done in certain cases. Empirical antibiotics were started immediately, antifungal and antiviral tretements were recieved according to the guidelines.
The different diagnostic modalities were analysed in addition to the results of treatment by different classes of antibiotics. The most frequent diagnosis in our study were AML (55 pts), followed by ALL (27pts), NHL (35 pts).The disease status was found to be highly significant and affects the control of neutropenic fever episode. The more the patient developed neutropenic episodes the more the risk of mortality. In our study, the MASCC score was highly significant. 62% of the identified pathogens were gram positive detected by blood culture, while gram negative bacteria were the commonest pathogens identified by other diagnostic modalities.
Multivariate analysis to determine pretreatment variables of independent prognostic value
|Variable||odds ratio||95% CI||P-value||Weighted partial score|
|Previous FN episode||1.47||0.307||7.023||0.63||-|
|Prevoius fungal infection||1.905||0.407||8.91||0.413||-|
Many risk factors affect the outcome of FN and should be taken into consideration for every pt.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.